CRB 4101
Alternative Names: CRB-4101Latest Information Update: 13 Jan 2023
At a glance
- Originator CR Pharmaceutical
- Class Cardiovascular therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cardiovascular disorders
Most Recent Events
- 16 Nov 2022 Phase-I clinical trials in Cardiovascular disorders (In volunteers) in China (PO) (NCT05641181)